Search PubMed⌕ Search

Biomedical subjects

J Kuska

Publications and source records attributed to J Kuska.

At least 55 records · Page 3Linked to original sources
PubMed1982

Relation between middle molecules and parathyroid hormone in patients with chronic renal failure.

In 10 moderately and 41 severely uremic patients the relation between serum parathyroid hormone (PTH) and middle molecule fraction 2 (MMS fr. 2-corresponding to MMS peak 7 of Fürst) was investigated. A significant correlation between PTH and MMS fr. 2 levels was found. This correlation was even better between PTH levels and MMS fr. 2/creatinine ratios. We would like to propose that PTH is one of several factors regulating middle molecule levels in uremic patients and that some 'toxic' effects of PTH may be mediated by middle molecules.

Blood Urea Nitrogen↗
PubMed1981

25-hydroxyvitamin D in patients with essential hypertension.

Plasma 25-OH-D levels of normotensive and hypertensive subjects living in a highly industrial and in a nonindustrial area, were estimated. Significantly higher values were found in normotensive subjects than in hypertensive patients. Severity of arterial hypertension was not related to plasma 25-OH-D. Both groups of subjects (normotensive and hypertensive) living in the industrial area with high air pollution had lower 25-OH-D concentrations than those living in the nonindustrial region. Data presented in this paper suggest that antihypertensive treatment by pharmacologic agents exerts a depressive effect on plasma 25-OH-D level.

25-Hydroxyvitamin D 2↗
PubMed1980

Serum 25-hydroxyvitamin D in patients with chronic renal failure on long-term treatment with high doses of vitamin D2.

The present study was aimed at answering the following two questions: (1) What is the effect of high dose vitamin D treatment on the serum level of 25-hydroxyvitamin D (25-OH-D) in patients with chronic renal failure (CRF)? (2) Is there any effect of urinary protein loss on the serum 25-OH-D levels during treatment with pharmacological doses of vitamin D? 42 patients with CRF were studied. They were treated conservatively by a low protein diet and received 15 mg of vitamin D2 once a week. Long-term administration of vitamin D caused a significant (5- to 7-fold) increase of plasma 25-OH-D level irrespective of the degree of proteinuria. This increase was noted only during the first 5 months of vitamin D2 treatment. Surprisingly only in some patients moderate hypercalcemia (> 2.75 mmol/l) was found. From the results obtained it is concluded that (1) patients with CRF differ from normal subjects in handling of high doses of vitamin D and (2) high dosage treatment with vitamin D may prevent hypocalcemia in patients with CRF in spite of high proteinuria.

Adult↗
PubMed1979

[Parathormone, calcitonin, 25-hydroxycalciferol and bone histology in patients with chronic renal insufficiency].

In 18 patients with chronic renal failure the parathormone (PTH), calcitonin (CT) and 25-OH-D blood levels were estimated before and after an intravenous calcium load. In ten patients the above mentioned biochemical parametres were confronted with histological findings obtained in bone biopsy material. Significantly elevated levels of PTH and CT were found while those of 25-OH-D were normal. Serum PTH decreased after a calcium load. In contrast to healthy persons no increase of serum CT was stated. Significant positive correlations were found between PTH and CT levels in blood serum as well as between the mineralized bone volume and 25-OH-D levels in serum. In addition a significant negative correlation was stated between the osteoid volume and 25-OH-D levels in blood serum. From the results obtained it is concluded, that from estimations of PTH, CT and 25-OH-D in blood serum histological alterations in bone biopsy material from chronic uremic patients can not be predicted. Beside secondary hyperparathyreoidism, relative deficiency of CT and active vitamin D metabolites other factors are also involved in the pathogenesis of renal osteodystrophy.

Adult↗
PubMed1978

Effects of 1alpha-hydroxyvitamin D3 on serum calcium and immunoreactive parathyroid hormone in patients with chronic renal insufficiency.

Six patients with chronic renal failure on regular dialysis treatment were given low doses (0.5--1.0 microgram/day) of 1alpha-hydroxyvitamin D3, monitoring the serum calcium, inorganic phosphate, immunoreactive parathyroid hormone concentration (IPTH) and alkaline phosphatase activity. The serum calcium rose in all patients after 7 days' treatment, in some subjects to hypercalcemic range; this effect persisted 6--14 days after withdrawal of 1alpha-hydroxyvitamin D3. The elevated serum IPTH rose in the first days of treatment, but later decreased to normal values. It is suggested that active vitamin D metabolites are necessary for normal response of parathyroid glands to variation in serum calcium. Low-dose 1alpha-hydroxyvitamin D3 treatment appears to be a promising method of correcting hypocalcemia and secondary hyperparathyroidism in chronic renal failure. Careful control of serum calcium is necessary, as hypercalcemia may occur even after minute doses of 1alpha-hydroxyvitamin D3.

Adolescent↗